ARMoR

Authors: Tim Laurence, David McKinney, Mo Putera Pull incentives for new antibiotics are premised on strong public health value and a reasonable return on investment, yet for many new antibiotics that value is uncertain. What is needed, and what has not been supplied, is a clear articulation of the health and economic impact an innovative antibiotic could deliver, and the pricing or subscription payment that impact could justify. Many antibiotics receiving regulatory approval in recent years...

Support for antimicrobial development through push and pull incentives is a necessary part of ensuring sustainable antimicrobial R&D and access . Despite calls for additional action, progress remains slow. In this brief, we aim to investigate and address key uncertainties around the adoption of these incentive mechanisms and add further urgency to deployment. Key messages Antimicrobial development faces both scientific and economic barriers. Despite growing political attention, current...

As part of the EcoAMR series the Center for Global Development (CGD) recently published a modelling study on the global direct inpatient...